


ZoomRx *Brand* *Performance* Tracking Capabilities

APRIL 2025




ZoomRx's *approach* has all the critical elements needed for a successful ATU



GLOBAL EXPERIENCE

14+ years of experience conducting Global tracking research



PROPRIETARY PANEL

>50k HCPs and >2k patients **across the Globe** in our proprietary panel



INNOVATIVE TECHNOLOGY

Collect **live** responses and ask **real-time open ended** follow-up questions for **additional context**



INDUSTRY BENCHMARKS

Define what **brand performance** looks like using >1 million benchmark datapoints



ANALYSIS FRAMEWORKS

Get actionable recommendations on promotions using our analysis frameworks

ZoomRx global *experience*

This is familiar territory for us

We have over 15 years of experience conducting integrated, franchise-wide, global research and a proven track record of taking over research programs from incumbents


WE HAVE DONE THIS IN



GLOBAL EXPERIENCE TIERING BY COUNTRY

- Tier 1 US, Canada, Europe, Japan
- Tier 2 Latin America, Asia
- Tier 3 Remaining countries

WE HAVE DONE THIS WITH



17/20

LARGEST GLOBAL PHARMA COMPANIES
PARTNER WITH ZOOMRX FOR TRACKING

ZoomRx *panel* for global studies



Deep network of global and local partners* and regional expertise in addition to proprietary panel



Dedicated global recruitment and compliance team



Universal, GDPR-enabled technology embedded platform

ZOOMRX PANEL



20+
Specialties



52800+
HCPs in the ZoomRx US Panel




2100+
life sciences consultants
across the globe

In addition, ZoomRx also has tenured relationships with Global **recruitment partners** such as M3, Schlesinger, Sermo, Sago, Reckner, WebMD, etc. and other country-specific, local vendors*

Technology embedded *innovative* platform


VOICE OF CUSTOMER INSIGHTS

ZoomRx Voice Response Technology allows respondents to explain "why" by simply speaking into survey platform.



CONTEXT SPECIFIC AI-ENABLED FOLLOW UP

ZoomRx's platform allows you to collect context specific real-time open ends by generating probing questions within your studies




Encourages deeper respondent thought and insight

Largest *benchmark* database

Zoomrx has over 2 MILLION+ ATU industry benchmarks

- Aided Brand Awareness
- Aided Clinical Trial Awareness
- Drivers and Barriers
- NPS Score
- Stated Attribute Importance
- Product Perception
- And more...

With 500+ brands tracked, ZoomRx has custom analogs that contextualize performance and reveal what success looks like in any market situation




With 500+ brands tracked, ZoomRx has custom analogs that contextualize performance and reveal what success looks like in any market situation

Integrated analysis *frameworks*



ADOPTION FUNNEL




The Adoption Funnel depicts the journey the HCP takes from encountering the brand to becoming a brand advocate. It helps deduce the prescribing journey and fix "leaks" in the funnel

BRAND EQUITY MATRIX



ZoomRx Brand Equity Matrix allows commercial teams to track the relative position of all brands within a therapeutic area to inform commercial strategies to further differentiate and increase share

ATTRIBUTE IMPORTANCE MAP



There is always more than what meets the eye. The derived vs. stated importance map is a scatter plot that helps us understand how intrinsic factors impact a brand's adoption

HCP ARCHETYPING

	Bold Believers (n=17)	Pragmatic Prescribers (n=15)	Static Sequencers (n=2)
Segments			
Key Beliefs	<ul style="list-style-type: none"> Consider (PRODUCT 1) superior to other (MCA 1)s Survival (PFS, OS) endpoints are top unmet needs, efficacy primarily drives treatment decisions Adopt novel agents quickly Selective in reserving (MCA 2) for high-disease burden patients, and less receptive to (L (PRODUCT 1)) Not likely to believe (PRODUCT 1) in 1L will become SOC 	<ul style="list-style-type: none"> Consider (PRODUCT 1) superior to other (MCA 1)s Survival (PFS, OS) endpoints, followed by safety, are top unmet needs Adopt novel agents quickly Selective in reserving (MCA 2) for high-disease burden patients, and less receptive to (L (PRODUCT 1)) 	<ul style="list-style-type: none"> Reserve (PRODUCT 1) for 2L in anticipation of (MUTATION 1) mutations Efficacy and safety are equally top unmet needs Wait to adopt new regimens until they are well established Prior to prescriber regimens with the same (MCA 1) across L0s (MCA 1)s

While HCP behaviors provide insights on their own, archotyping uncovers how beliefs and actions interact, shaping brand perceptions and engagement.



Get in touch

info@zoomrx.com